Johan Jansson

Takeda (United States) — United States

Medicine · Health Sciences

7h-index451citations22works10.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(10), T-cell and B-cell Immunology(6), Immune Cell Function and Interaction(6), Inflammatory Bowel Disease(4), Acute Lymphoblastic Leukemia research(4)

Publications22 total

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma
Journal of Cancer·2025· 1 citedOpen Access
Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study
International Journal of Hematology·2025· 2 citedOpen Access
Practical considerations of promising zone design for interim sample size Re-estimation: An application to GRAPHITE for graft vs host disease
Contemporary Clinical Trials·2024· 1 citedOpen Access
Population pharmacokinetic modeling of vedolizumab for graft‐versus‐host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant
Pharmacology Research & Perspectives·2024· 1 citedOpen Access
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
Nature Medicine·2024· 47 citedOpen Access
A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease
Bone Marrow Transplantation·2021· 17 citedOpen Access
Sa1880 DOSE ESCALATION OF SUBCUTANEOUS VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: A POST HOC ANALYSIS OF THE VISIBLE TRIAL DATA
Gastroenterology·2020· 2 cited
Sa1878 POST HOC EXAMINATION OF VISIBLE 1 DATA FOR BASELINE PREDICTORS OF RESPONSE TO 2 OR 3 IV DOSES OF VEDOLIZUMAB FOR ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Gastroenterology·2020
Sa1879 EFFICACY AND SAFETY OF VEDOLIZUMAB REINITIATION FOLLOWING TREATMENT INTERRUPTION: POST HOC ANALYSIS OF THE VISIBLE TRIAL DATA
Gastroenterology·2020· 1 cited
P403 Post hoc examination of VISIBLE 1 data for baseline predictors of response to 2 or 3 IV doses of vedolizumab for adults with moderate-to-severe ulcerative colitis
Journal of Crohn s and Colitis·2020Open Access
P510 Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: A post hoc analysis of the VISIBLE trial data
Journal of Crohn s and Colitis·2020· 4 citedOpen Access
Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Blood Advances·2019· 45 citedOpen Access
A Phase 1b Study of Intravenous Vedolizumab Plus Standard of Care for Graft-Versus-Host Disease Prophylaxis in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: 6-Month Results
Blood·2018· 1 cited
Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition
Molecular Neurobiology·2015· 65 citedOpen Access
Improved Cell Therapy Protocols for Parkinson's Disease Based on Differentiation Efficiency and Safety of hESC-, hiPSC-, and Non-Human Primate iPSC-Derived Dopaminergic Neurons
Stem Cells·2013· 223 citedOpen Access
CD23+CD21highCD1dhigh B Cells in Inflamed Lymph Nodes Are a Locally Differentiated Population with Increased Antigen Capture and Activation Potential
The Journal of Immunology·2012· 22 citedOpen Access
Leukemia Free Survival Is Associated with Presence of Leukemia Reactive Antibodies In Allogeneic Transplant Recipients
Blood·2010
Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects
Leukemia Research·2010· 8 cited
Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with Donor Lymphocyte Infusion and/or Vaccination
Biology of Blood and Marrow Transplantation·2010· 2 citedOpen Access
Differential gene expression in acute lymphoblastic leukemia cells surviving allogeneic transplant
Cancer Immunology Immunotherapy·2010· 4 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Jingjing Chen(6), Andrew Campbell(6), Craig A. Mullen(6), Yi‐Bin Chen(5), William J. Sandborn(5), Ninfa Candela(5), Karen Lasch(5), Krisztina Kisfalvi(5), Guillermo Rossiter(4), Mona Akbari(4), Chunlin Chen(4), Yu-Chiao Hsu(4), Yngvar Fløisand(3), Anne S. Renteria(3), Syed M. Quadri(3), Andrejus Parfionovas(3), Steven M. Devine(3), Sharif Uddin(3), Gaynor A. Smith(2), Teresia Osborn(2)